UNSPSC 51203602: Loxanast

This classification denotes an immunosuppressant with the molecular formula C14H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 746YWK1B07, chemically known as cyclohexanecarboxylic acid, 1-methyl-4-(4-methylpentyl)-, cis- but more generally known as loxanast, which bears US NIH Compound Identifier 68890. European Medicines Agency schedules Loxanast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08606MIG. The term LOXANAST is an International Non-Proprietary Name.

UNSPSC 51203602 Loxanast, a Commodity code, covers naloxone (also known as Narcan) and related opioid-reversal pharmaceuticals that state and local governments procure for emergency medical response, community health initiatives, and pharmacy benefit programs. Recent solicitations show state and local buyers acquiring naloxone units in bulk quantities alongside safe drug deactivation systems, generic multi-source pharmaceuticals through cooperative purchasing vehicles, and therapeutic pharmacy programs that route prescription fulfillment through direct-to-manufacturer channels. Issuing bodies include county health departments, municipal fire rescue divisions, state health and human services agencies, and statewide cooperative purchasing alliances that aggregate demand across multiple jurisdictions and participating states.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a two-year initial term and one-year renewal option on a fixed-fee basis; the City of Tampa's Purchasing Department released IFB 26P00145 in March 2026 for medical and first aid supplies including respiratory equipment and medical consumables for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000.00 and a 5 percent bid discount sheltered for certified Small Local Business Enterprises. The Texas Health and Human Services Commission posted an exploratory Request for Information (RFI HHS0017013) in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program aimed at improving prescription fulfillment efficiency. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities, with proposals due March 26, 2026 and contract awards effective July 1, 2026, requiring vendors to work through three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards.